Literature DB >> 27754861

Deciphering assumptions about stepped wedge designs: the case of Ebola vaccine research.

Adélaïde Doussau1, Christine Grady1.   

Abstract

Ethical concerns about randomising persons to a no-treatment arm in the context of Ebola epidemic led to consideration of alternative designs. The stepped wedge (SW) design, in which participants or clusters are randomised to receive an intervention at different time points, gained popularity. Common arguments in favour of using this design are (1) when an intervention is likely to do more good than harm, (2) all participants should receive the experimental intervention at some time point during the study and (3) the design might be preferable for practical reasons. We examine these assumptions when considering Ebola vaccine research. First, based on the claim that a stepped wedge design is indicated when it is likely that the intervention will do more good than harm, we reviewed published and ongoing SW trials to explore previous use of this design to test experimental drugs or vaccines, and found that SW design has never been used for trials of experimental drugs or vaccines. Given that Ebola vaccines were all experimental with no prior efficacy data, the use of a stepped wedge design would have been unprecedented. Second, we show that it is rarely true that all participants receive the intervention in SW studies, but rather, depending on certain design features, all clusters receive the intervention. Third, we explore whether the SW design is appealing for feasibility reasons and point out that there is significant complexity. In the setting of the Ebola epidemic, spatiotemporal variation may have posed problematic challenges to a stepped wedge design for vaccine research. Finally, we propose a set of points to consider for scientific reviewers and ethics committees regarding proposals for SW designs. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Keywords:  Biostatistics; Clinical trials; Drugs and Drug Industry; Policy Guidelines/Inst. Review Boards/Review Cttes.; Research Ethics

Mesh:

Substances:

Year:  2016        PMID: 27754861     DOI: 10.1136/medethics-2015-103292

Source DB:  PubMed          Journal:  J Med Ethics        ISSN: 0306-6800            Impact factor:   2.903


  8 in total

1.  Rigorous Clinical Trial Design in Public Health Emergencies Is Essential.

Authors:  Susan S Ellenberg; Gerald T Keusch; Abdel G Babiker; Kathryn M Edwards; Roger J Lewis; Jens D Lundgren; Charles D Wells; Fred Wabwire-Mangen; Keith P W J McAdam
Journal:  Clin Infect Dis       Date:  2018-04-17       Impact factor: 9.079

Review 2.  Design of vaccine efficacy trials during public health emergencies.

Authors:  Natalie E Dean; Pierre-Stéphane Gsell; Ron Brookmeyer; Victor De Gruttola; Christl A Donnelly; M Elizabeth Halloran; Momodou Jasseh; Martha Nason; Ximena Riveros; Conall H Watson; Ana Maria Henao-Restrepo; Ira M Longini
Journal:  Sci Transl Med       Date:  2019-07-03       Impact factor: 17.956

3.  Vaccine testing for emerging infections: the case for individual randomisation.

Authors:  Nir Eyal; Marc Lipsitch
Journal:  J Med Ethics       Date:  2017-04-10       Impact factor: 2.903

4.  Ethical and epistemic issues in the design and conduct of pragmatic stepped-wedge cluster randomized clinical trials.

Authors:  Carole A Federico; Patrick J Heagerty; John Lantos; Pearl O'Rourke; Vasiliki Rahimzadeh; Jeremy Sugarman; Kevin Weinfurt; David Wendler; Benjamin S Wilfond; David Magnus
Journal:  Contemp Clin Trials       Date:  2022-02-15       Impact factor: 2.261

5.  Research priorities during infectious disease emergencies in West Africa.

Authors:  Morenike Oluwatoyin Folayan; Bridget Haire; Dan Allman; Aminu Yakubu; Muhammed O Afolabi
Journal:  BMC Res Notes       Date:  2018-03-01

6.  Reporting of stepped wedge cluster randomised trials: extension of the CONSORT 2010 statement with explanation and elaboration.

Authors:  Karla Hemming; Monica Taljaard; Joanne E McKenzie; Richard Hooper; Andrew Copas; Jennifer A Thompson; Mary Dixon-Woods; Adrian Aldcroft; Adelaide Doussau; Michael Grayling; Caroline Kristunas; Cory E Goldstein; Marion K Campbell; Alan Girling; Sandra Eldridge; Mike J Campbell; Richard J Lilford; Charles Weijer; Andrew B Forbes; Jeremy M Grimshaw
Journal:  BMJ       Date:  2018-11-09

7.  Ethics preparedness: facilitating ethics review during outbreaks - recommendations from an expert panel.

Authors:  Abha Saxena; Peter Horby; John Amuasi; Nic Aagaard; Johannes Köhler; Ehsan Shamsi Gooshki; Emmanuelle Denis; Andreas A Reis; Raffaella Ravinetto
Journal:  BMC Med Ethics       Date:  2019-05-06       Impact factor: 2.652

8.  Response adaptive intervention allocation in stepped-wedge cluster randomized trials.

Authors:  Michael J Grayling; James M S Wason; Sofía S Villar
Journal:  Stat Med       Date:  2022-01-21       Impact factor: 2.497

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.